Johnson & Johnson Posts Earnings Beat, Ups Outlook

Johnson & Johnson Posts Earnings Beat, Ups Outlook
By Kityvankova (Own work) [Public domain], via Wikimedia Commons

Johnson and Johnson released its second quarter earnings report before opening bell this morning, posting adjusted earnings of $1.71 per share, a 3.9% decline, on revenue of $17.8 billion, an 8.8% decline year over year. Analysts had been looking for earnings of $1.68 per share and $17.76 billion in sales. In the same quarter last year, Johnson & Johnson reported sales of $$19.5 billion.

Play Quizzes 4

Reported earnings were $1.61 per share, compared to last year’s $1.51 per share.

Johnson & Johnson’s earning by segment

Johnson & Johnson saw $3.5 billion in sales for its Worldwide Consumer division, a 7% year over year decline. The decline was due to a negative impact of 9.3% due to currency exchange rates. Operationally, the segment saw sales increase 2.3%. Domestic sales in the division increased 2.7%, while international sales fell 12.2%, including a 2.1% operational increase and a negative impact of 14.3% due to currencies. Sales of Zyrtec, Tylenol, feminine protection products and Listerine contributed to the results.

Fund Manager Profile: Zhang Hui Of China’s Southern Asset Management

investHistorically, the Chinese market has been relatively isolated from international investors, but much is changing there now, making China virtually impossible for the diversified investor to ignore. Earlier this year, CNBC pointed to signs that Chinese regulators may start easing up on their scrutiny of companies after months of clamping down on tech firms. That Read More

Worldwide Pharmaceutical sales fell 6.6% to $7.9 billion. Currencies also weighed on the pharmaceutical division, negatively impacting the results by 7.6%. Operationally, the segment grew 1%. Domestic sales in the division fell 1.5%, while international sales declined 12.7%. The negative impact from currencies was 16.5% for the segment.  Drivers of sales in the division include Hepatitis C drugs, which saw a 9.7% underlying operational growth globally. Other pharmaceuticals which drove sales during the quarter include type 2 diabetes drug Invokana/ Invokamet, blood cancer drug Imbruvica, and prostate cancer drug Zytiga.

Worldwide Medical Devices saw a 12.2% decline in sales to $6.4 billion, including a negative impact of 7.5% from currencies.

Johnson & Johnson ups guidance

Johnson & Johnson also increased its guidance for adjusted earnings for the full year. The consumer products company now expects adjusted earnings of between $6.10 and $6.20 per share. The previous guidance suggested earnings of between $6.04 and $6.19 per share for the full 2015 fiscal year.

Shares of Johnson & Johnson were up 0.43% at $100.70 per share.

Updated on

Michelle Jones is editor-in-chief for and has been with the site since 2012. Previously, she was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Email her at
Previous article What China’s Stock Market Turmoil Means For Investors
Next article Wells Fargo & Co Stock Slides After Revenue Miss

No posts to display